Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan.
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata-City, Yamagata, 990-9585, Japan.
Respir Investig. 2024 Jul;62(4):663-668. doi: 10.1016/j.resinv.2024.05.007. Epub 2024 May 17.
Although respiratory tract infection is a significant factor that triggers exacerbation of chronic obstructive pulmonary disease (COPD), the benefit of antibiotics for patients with COPD exacerbation remains controversial. It is necessary to evaluate the efficacy and safety of antibiotics versus placebo in such patients.
We conducted a systematic review and meta-analysis of randomized controlled trials of antibiotics versus placebo for the treatment of COPD exacerbation, and compared the frequencies of treatment failure, mortality, and adverse events between patients treated with antibiotics and those treated with placebo.
A total of six studies were included in this meta-analysis. The frequency of treatment failure was significantly lower in the antibiotic-treated patients compared to the placebo-treated patients (odds ratios [OR] 0.50, 95% confidence intervals [CI] 0.35-0.71, p = 0.0001). There was no significant difference between the two groups in mortality (OR 0.44, 95% CI 0.05-3.76, p = 0.45) or frequency of adverse events (OR 1.05, 95% CI 0.75-1.48, p = 0.78).
In the current systematic review and meta-analysis, we found that antibiotics were superior to placebo in patients with exacerbated COPD, as shown by the lower treatment failure rate.
虽然呼吸道感染是引发慢性阻塞性肺疾病(COPD)加重的重要因素,但抗生素治疗 COPD 加重的疗效仍存在争议。有必要评估抗生素与安慰剂治疗 COPD 加重患者的疗效和安全性。
我们对抗生素与安慰剂治疗 COPD 加重的随机对照试验进行了系统评价和荟萃分析,并比较了抗生素治疗组与安慰剂治疗组的治疗失败率、死亡率和不良事件发生率。
共有 6 项研究纳入了本次荟萃分析。抗生素治疗组的治疗失败率明显低于安慰剂治疗组(比值比 [OR] 0.50,95%置信区间 [CI] 0.35-0.71,p = 0.0001)。两组间死亡率(OR 0.44,95%CI 0.05-3.76,p = 0.45)或不良事件发生率(OR 1.05,95%CI 0.75-1.48,p = 0.78)均无显著差异。
在本次系统评价和荟萃分析中,我们发现抗生素在 COPD 加重患者中的疗效优于安慰剂,表现为治疗失败率较低。